<< Back to News

System Formulary Update
Filgrastim

Situation

Short-acting granulocyte colony stimulating factors (G-CSF) were standardized across UNC Health in July 2021. A recent pricing analysis revealed filgrastim-aafi (Nivestym®) cost has fallen below that of tbo-filgrastim (Granix®).

Background

The following medications were reviewed:  filgrastim-aafi (Nivestym®) and tbo-filgrastim (Granix®).

Assessment/Recommendation

Change effective: Tuesday, February 1^st

System P&T voted to make the following changes to the UNC Health Medication Formulary:

• Change the UNC Health preferred filgrastim agent for inpatient use to filgrastim-aafi (Nivestym®)
• Change the UNC Health preferred filgrastim agent for outpatient use to filgrastim-aafi (Nivestym®)
  • Tbo-filgrastim (Granix®) to remain on formulary for outpatient use only for patients previously on tbo-filgrastim (Granix®) or those with insurance restrictions that require tbo-filgrastim (Granix®) or do not cover filgrastim-aafi (Nivestym®)
  • Filgrastim-sndz (Zarxio) to remain on formulary for outpatient use only for patients previously on Zarxio or those with insurance restrictions that require filgrastim-sndz (Zarxio®) or do not cover filgrastim-aafi (Nivestym®) or tbo-filgrastim (Granix®).